1. Home
  2. MYFW vs LCTX Comparison

MYFW vs LCTX Comparison

Compare MYFW & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

MYFW

First Western Financial Inc.

HOLD

Current Price

$26.10

Market Cap

220.8M

Sector

Finance

ML Signal

HOLD

Logo Lineage Cell Therapeutics Inc.

LCTX

Lineage Cell Therapeutics Inc.

HOLD

Current Price

$1.62

Market Cap

407.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MYFW
LCTX
Founded
2002
1990
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
220.8M
407.7M
IPO Year
2018
N/A

Fundamental Metrics

Financial Performance
Metric
MYFW
LCTX
Price
$26.10
$1.62
Analyst Decision
Buy
Strong Buy
Analyst Count
2
4
Target Price
$24.25
$4.25
AVG Volume (30 Days)
29.4K
1.3M
Earning Date
01-22-2026
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
391.62
N/A
EPS
1.28
N/A
Revenue
$95,514,000.00
$10,816,000.00
Revenue This Year
$15.96
$6.32
Revenue Next Year
$13.77
$124.49
P/E Ratio
$20.51
N/A
Revenue Growth
19.92
24.05
52 Week Low
$17.10
$0.37
52 Week High
$26.50
$2.09

Technical Indicators

Market Signals
Indicator
MYFW
LCTX
Relative Strength Index (RSI) 67.59 41.61
Support Level $25.92 $1.63
Resistance Level $26.33 $1.77
Average True Range (ATR) 0.51 0.08
MACD 0.01 -0.01
Stochastic Oscillator 77.99 6.82

Price Performance

Historical Comparison
MYFW
LCTX

About MYFW First Western Financial Inc.

First Western Financial Inc is a financial holding company that provides a fully integrated suite of wealth management services on its private trust bank platform, which includes a comprehensive selection of deposit, loan, trust, wealth planning, and investment management products and services. The company has two operating segments; The Wealth Management segment consists of operations relative to the Company's fully integrated wealth management products and services, and The Mortgage segment consists of operations relative to the Company's residential mortgage service offerings. The bank derives its majority revenue from the wealth management segment.

About LCTX Lineage Cell Therapeutics Inc.

Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.

Share on Social Networks: